BioLargo Current Valuation vs. Total Debt
| BLGO Stock | USD 0.20 0.01 5.26% |
For BioLargo profitability analysis, we use financial ratios and fundamental drivers that measure the ability of BioLargo to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well BioLargo utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between BioLargo's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of BioLargo over time as well as its relative position and ranking within its peers.
BioLargo |
BioLargo Total Debt vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining BioLargo's current stock value. Our valuation model uses many indicators to compare BioLargo value to that of its competitors to determine the firm's financial worth. BioLargo is rated below average in current valuation category among its peers. It is rated below average in total debt category among its peers making up about 0.01 of Total Debt per Current Valuation. The ratio of Current Valuation to Total Debt for BioLargo is roughly 144.06 . Comparative valuation analysis is a catch-all model that can be used if you cannot value BioLargo by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for BioLargo's OTC Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.BioLargo Current Valuation vs. Competition
BioLargo is rated below average in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Materials industry is currently estimated at about 122.59 Billion. BioLargo adds roughly 52.87 Million in current valuation claiming only tiny portion of all equities under Materials industry.
BioLargo Total Debt vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
BioLargo |
| = | 52.87 M |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
BioLargo |
| = | 367 K |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
BioLargo Total Debt vs Competition
BioLargo is rated below average in total debt category among its peers. Total debt of Materials industry is currently estimated at about 917.66 Billion. BioLargo adds roughly 367,000 in total debt claiming only tiny portion of all equities under Materials industry.
BioLargo Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in BioLargo, profitability is also one of the essential criteria for including it into their portfolios because, without profit, BioLargo will eventually generate negative long term returns. The profitability progress is the general direction of BioLargo's change in net profit over the period of time. It can combine multiple indicators of BioLargo, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
BioLargo, Inc. invents, develops, and commercializes various platform technologies. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California. Biolargo operates under Chemicals classification in the United States and is traded on OTC Exchange. It employs 31 people.
BioLargo Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on BioLargo. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of BioLargo position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the BioLargo's important profitability drivers and their relationship over time.
Learn to be your own money manager
Our tools can tell you how much better you can do entering a position in BioLargo without increasing your portfolio risk or giving up the expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate risk-adjusted returns of your individual positions relative to your overall portfolio.Did you try this?
Run Portfolio Center Now
Portfolio CenterAll portfolio management and optimization tools to improve performance of your portfolios |
| All Next | Launch Module |
Use Investing Themes to Complement your BioLargo position
In addition to having BioLargo in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run ESG Investing Thematic Idea Now
ESG Investing
Sustainable investments that promote the conservation of the natural world, social resposibility, freindly employees policies and strong governance. The ESG Investing theme has 51 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize ESG Investing Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in BioLargo OTC Stock
To fully project BioLargo's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of BioLargo at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include BioLargo's income statement, its balance sheet, and the statement of cash flows.